Henan Taloph Pharmaceutical Stock Co.,Ltd (SHA:600222)
China · Delayed Price · Currency is CNY 6.68
+0.01 (0.15%)
At close: Feb 13, 2026
SHA:600222 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,782 | 1,936 | 2,065 | 1,945 | 1,602 | 1,416 |
Other Revenue | 5.2 | 5.2 | 4.95 | 15.33 | 2.83 | 1.4 |
| 1,788 | 1,941 | 2,070 | 1,961 | 1,605 | 1,417 | |
Revenue Growth (YoY) | -9.15% | -6.21% | 5.57% | 22.20% | 13.23% | 8.03% |
Cost of Revenue | 1,354 | 1,441 | 1,508 | 1,492 | 1,148 | 1,046 |
Gross Profit | 433.29 | 500.1 | 561.55 | 468.4 | 456.85 | 370.88 |
Selling, General & Admin | 254.72 | 307.58 | 339.5 | 317.51 | 246.89 | 211.37 |
Research & Development | 61.88 | 100.89 | 127.71 | 116.52 | 56.5 | 63.66 |
Other Operating Expenses | 9.25 | 8.63 | 6.54 | 8.42 | 2.59 | 7.08 |
Operating Expenses | 336.73 | 424.2 | 485.6 | 476.27 | 331.51 | 294.65 |
Operating Income | 96.56 | 75.9 | 75.94 | -7.87 | 125.34 | 76.23 |
Interest Expense | -60.29 | -59.64 | -54.37 | -64.63 | -83.84 | -74.44 |
Interest & Investment Income | 4.95 | 6.37 | 2.17 | 2.22 | 6.74 | 12.06 |
Other Non Operating Income (Expenses) | -0.23 | -1.51 | 10.8 | -1.56 | -2.46 | -3.44 |
EBT Excluding Unusual Items | 40.99 | 21.12 | 34.54 | -71.84 | 45.78 | 10.4 |
Gain (Loss) on Sale of Investments | 3.01 | 7.94 | -6.42 | -11.87 | -10.17 | 2.38 |
Gain (Loss) on Sale of Assets | -0.05 | 0.13 | 0.54 | 0.03 | -1.57 | 0.2 |
Asset Writedown | -4.71 | - | - | -0.15 | -29.9 | - |
Legal Settlements | - | - | - | -11.61 | -1.62 | - |
Other Unusual Items | 5.72 | 5.88 | 14.31 | 12.59 | 4.93 | 16.25 |
Pretax Income | 44.95 | 35.07 | 42.96 | -82.85 | 7.45 | 29.24 |
Income Tax Expense | -9.07 | -18.42 | -1.87 | -7.09 | 0.67 | 1.64 |
Earnings From Continuing Operations | 54.02 | 53.5 | 44.83 | -75.76 | 6.78 | 27.6 |
Minority Interest in Earnings | -7.07 | -2.97 | -1.27 | 3.56 | -0.78 | 1.65 |
Net Income | 46.95 | 50.53 | 43.56 | -72.2 | 6 | 29.24 |
Net Income to Common | 46.95 | 50.53 | 43.56 | -72.2 | 6 | 29.24 |
Net Income Growth | -47.47% | 16.00% | - | - | -79.50% | -34.16% |
Shares Outstanding (Basic) | 554 | 556 | 563 | 562 | 560 | 547 |
Shares Outstanding (Diluted) | 554 | 556 | 563 | 562 | 560 | 547 |
Shares Change (YoY) | -0.64% | -1.12% | 0.07% | 0.36% | 2.52% | -1.68% |
EPS (Basic) | 0.08 | 0.09 | 0.08 | -0.13 | 0.01 | 0.05 |
EPS (Diluted) | 0.08 | 0.09 | 0.08 | -0.13 | 0.01 | 0.05 |
EPS Growth | -47.13% | 17.31% | - | - | -80.00% | -33.04% |
Free Cash Flow | -71.71 | -76.82 | 0.6 | -191.03 | 60.58 | 0.77 |
Free Cash Flow Per Share | -0.13 | -0.14 | 0.00 | -0.34 | 0.11 | 0.00 |
Dividend Per Share | 0.042 | 0.028 | 0.018 | - | 0.010 | 0.016 |
Dividend Growth | 133.33% | 55.56% | - | - | -37.50% | - |
Gross Margin | 24.24% | 25.76% | 27.13% | 23.89% | 28.47% | 26.17% |
Operating Margin | 5.40% | 3.91% | 3.67% | -0.40% | 7.81% | 5.38% |
Profit Margin | 2.63% | 2.60% | 2.10% | -3.68% | 0.37% | 2.06% |
Free Cash Flow Margin | -4.01% | -3.96% | 0.03% | -9.74% | 3.78% | 0.06% |
EBITDA | 147.88 | 127.2 | 127.23 | 39.37 | 169.33 | 117.65 |
EBITDA Margin | 8.27% | 6.55% | 6.15% | 2.01% | 10.55% | 8.30% |
D&A For EBITDA | 51.32 | 51.3 | 51.29 | 47.24 | 43.99 | 41.42 |
EBIT | 96.56 | 75.9 | 75.94 | -7.87 | 125.34 | 76.23 |
EBIT Margin | 5.40% | 3.91% | 3.67% | -0.40% | 7.81% | 5.38% |
Effective Tax Rate | - | - | - | - | 9.01% | 5.62% |
Revenue as Reported | 1,788 | 1,941 | 2,070 | 1,961 | 1,605 | 1,417 |
Advertising Expenses | - | 26.78 | 35.78 | 39.78 | 24.05 | 14.17 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.